Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis

Characteristics and Prognostic Factors of Pulmonary Fibrosis After COVID-19 Pneumonia

(2022) Elisabetta Cocconcelli et al.   Frontiers in Medicine

3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study

(2021) Xiaojun Wu et al.   Lancet Respiratory Medicine

Phenotyping long COVID

(2021) Robert Naeije et al.   EUROPEAN RESPIRATORY JOURNAL

1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study

(2021) Lixue Huang et al.   LANCET

Long covid—mechanisms, risk factors, and management

(2021) Harry Crook et al.   BMJ-British Medical Journal

Long-term chest CT follow-up in COVID-19 Survivors: 102–361 days after onset

(2021) Xi Yin et al.   Annals of Translational Medicine

Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19

(2021) Maxime Taquet et al.   PLOS MEDICINE

Clinical Characteristics of Coronavirus Disease 2019 in China

(2020) Wei-jie Guan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abnormal pulmonary function in COVID-19 patients at time of hospital discharge

(2020) Xiaoneng Mo et al.   EUROPEAN RESPIRATORY JOURNAL

Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection

(2020) Justine Frija-Masson et al.   EUROPEAN RESPIRATORY JOURNAL

Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19)

(2020) W. Joost Wiersinga et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The progression of computed tomographic (CT) images in patients with coronavirus disease (COVID-19) pneumonia

(2020) Pinggui Lei et al.   JOURNAL OF INFECTION

CT features of COVID-19 patients with two consecutive negative RT-PCR tests after treatment

(2020) Zhao Fu et al.   Scientific Reports

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

(2019) Toby M Maher et al.   Lancet Respiratory Medicine

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis

(2017) Steven D Nathan et al.   Lancet Respiratory Medicine

A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

(2014) Talmadge E. King et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

(2014) Luca Richeldi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

(2011) Paul W Noble et al.   LANCET

Pirfenidone in idiopathic pulmonary fibrosis

(2009) H. Taniguchi et al.   EUROPEAN RESPIRATORY JOURNAL